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ABSTRACT 
 
Soluble ST2, is a protein which acts as a decoy receptor for interleukin-33, and 
served as biomarker associated with left ventricular hypertrophy (LVH).  Few data 
exist in evaluating the effects of anti-hypertensive agents on the role-played form 
ST2 on regression of LVH. This study was designed to compare the effects of 
captopril and valsartan on blood pressures, plasma renin and soluble ST2 levels 
and regression of LVH in hypertensive mice models. Twenty-four male mice (Mus 
musculus L), were divided into four groups, namely aquadest/control, L-NAME, 
L-NAME + captopril and L-NAME + valsartan groups respectively. Mice blood 
pressures were measured on day 14th after induction with L-NAME extract 1.75 
mg/25g BW/day (pretreatment) and day 14th post treatment. Levels of plasma 
renin, sST2, and ventricular wall thicknesses reflecting LVHs, were measured on 
day 14th post treatment. Administration of L-NAME within 14 days resulted in 
making mice models to be hypertensive paralleled by an increase of Ventricular 
wall thickness. Treatment with captopril and valsartan lowered the blood pressures 
to normal level within the next 14 days. Valsartan and captopril treatment induced 
a significant decrease of plasma renin level. Valsartan, but not for captopril treat-
ment prevented wall thickness increase (p < 0.05), while plasma sST2 was not 
able to mirroring this effect. Captopril and valsartan had similar effect in lowering 
plasma renin level and   blood pressure, but sST2 seems to be not involved in LVH 
regression obtained in hypertensive mice models after blocking renin-angiotensin 
system. 
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Introduction 
Hypertension (HT) remains a major public 
health problem associated with the leading risk 
factor for morbidity and mortality [1]. The preva-
lence of this disease has been estimated to increase 
up to 29% of entire population in 2025 [2, 3]. 
Based on Health Research (Riset Kesehatan Da-
sar/Riskesdas) 2013 data, there are 25.8% of Indo-
nesian people suffering of hypertension [4].  If the 
total number of Indonesian people now are 
252,123,456, means that 65,048,110 people are 
hypertensives in Indonesia. 
Meta-analysis studies suggested that reducing 
systolic blood pressure to levels below currently 
guidelines recommended targets could reach to 
significantly reduction of the risk of cardiovascu-
lar disease and all-cause mortality [5, 6]. The most 
frequent organ damage complication in hyperten- 
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sive patients is left ventricle hypertrophy (LVH) 
which may result in heart failure (HF) [7, 8]. 
Therefore, intensive treatment for lowering blood 
pressure to the current guidelines recommended 
levels would lead to prevent LVH. 
Many studies, aimed to compare the effective-
ness of common anti-hypertensive drugs used in 
hypertensive patients, such as diuretics, beta-
blockers, calcium-channel blockers (CCBs), angi-
otensin converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs); already 
demonstrated a reduction in both cardiovascular 
mortality and morbidity with all of these drug clas-
ses [9, 10, 11].  Soluble ST2 is a blood protein that 
has confirmed to act as a decoy receptor for inter-
leukin-33. Soluble ST2 is also known to be mark-
edly involved into the process of mechanically 
overloaded cardiac myocytes [14, 15], and could 
represent a cardiac stress biomarker associated 
with LVH [16]. Moreover, in a meta-analysis 
plasma sST2 has been demonstrated to have a 
prognostic value with respect to all-cause and car-
diovascular death as well as the composite out-
come of all-cause death or HF hospitalization [33]. 
Previous studies already also have shown that 
plasma sST2 was not only useful biomarker for 
predicting development of stress cardiomyopathy 
[34] but also has prognostic role in patients with 
sepsis [35, 36] and correlated with left ventricular 
structure and function in patients with metabolic 
syndrome [37]. Renin is the well-known enzyme 
of the Renin Angiotensin Aldosteron System, 
which plays central role in the regulation of blood 
pressure and the development of LVH [12, 13].  
This study was conducted in order to measure, 
in hypertensive mice model, the level of plasma 
renin and Soluble Suppression of Tumorigenicity-
2 (sST2) as chemical potential effectors of left 
ventricular hypertrophy regression obtained as 
consequence of blood pressure reduction after 
ACE-inhibitor (Captopril) or ARB (Valsartan) 
treatment. 
 
Material and Methods 
This true experimental study using random-
ized posttest only control group design was con-
ducted at the laboratory of Animal Model Faculty 
of Medicine - Universitas Muhammadiyah Ma-
lang, Laboratory of Formulative Preparation and 
Laboratory of Integrated Chemistry, Pharmacy 
Study Program Faculty of Health Sciences – Uni- 
versitas Muhammadiyah Malang, from January to 
April 2015. The proposal of this study had been 
approved by Health Research Ethics Committee 
Faculty of Medicine, Universitas Brawijaya No. 
370/EC/KEPK/07/2015. 
 
Hypertensive mice models 
This study was done within 28 days, the first 
14 days were used for induction of hypertensive 
mice model and the next 14 days were used for 
treatment. As many of 24 male mice (Mus muscu-
lus L), 10 – 12 weeks old and 20-30 grams of body 
weights were included in this study. After one-
week acclimatization, the mice were randomly di-
vided into four groups, consisted of six mice in 
each group. Mice in group (A) were given 
aquadest only and used as negative control, while 
the group (B), (C) and (D) were given L-NAME 
extract 1.75 mg/25g BW/day diluted in drinking 
water for two weeks [17, 18, 19]. For the next 14 
days, the mice in group (B) were still given L-
NAME only, served as positive control group. At 
the same period of the next 14 days, mice in group 
(C) were given L-NAME plus captopril 0.0488 
mg/30g BW, and mice in group (D) were given L-
NAME plus valsartan 0.312 mg/30g BW orally af-
ter multiplied with 0.0026 as conversion factor 
from human dose to mouse [20]. Both of captopril 
and valsartan in those doses were diluted in 0.5 cc 
aquadest and given orally per sonde to each mouse 
by an expert technician. The mice blood pressures 
were examined on the 14 days (pretreatment) and 
the next 14 days (post treatment), while intracar-
dial blood sampling for measurement of plasma 
renin and sST2 levels and isolation of heart for his-
tological measurement of ventricular wall thick-
ness were conducted on the day 14th post treat-
ment. 
 
Measurement of mice blood pressures and mean 
arterial pressures (MAPs)  
Blood pressures (BP) of all mice were meas-
ured in mmHg. using the Blood Pressure Re-
corder. The 58500 BP RECORDER which is ba-
sically a recording Riva Rocci sphygmo-manome-
ter, has been conceived to provide an objective 
precise recording of the systolic and diastolic BP 
of every processed rodent. The BP recorder com-
bines three main systems, those are: 1) pressure 
generation-pressure monitoring system; 2) a pulse 
amplifier and 3) a thermal-array analog and digital 
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recording unit [21]. Blood pressures were meas-
ured after the mice acclimatized in quite condition 
for 10 minutes in the animal holder. The measure-
ments for each mouse were repeated three times to 
ensure the results obtained (systolic and diastolic 
values) constantly. The mean arterial pressures 
(MAPs) values were found by calculation using 
the formula of: MAP = (Systolic BP+2x Diastolic 
BP)/3 [22]. Those procedures were done individu-
ally on the day 14th of study (pretreatment), and on 
the next 14th day after treatment, before the mice 
were sacrificed.   
 
Measurement of plasma renin and sST2 level 
After the mice had been deep anesthetized us-
ing chloroform, cardiac puncture was done upon 
each mouse to take the blood and collect it into 
EDTA tubes, centrifuge at 5000 rpm at room tem-
perature for 15 minutes. Plasma samples were col-
lected and transferred to separate tubes and kept 
freeze at -20°C. Plasma renin level was analyzed 
by ELISA techniques by following the procedure 
which described on the kit leaflets and on 
Abcam’s IL-1 R4 ELISA Kit (ST2) protocol 
[23,24]. The value of plasma renin levels was 
showed in ng/mL and sST2 were showed in pg/mL 
 
Measurement of ventricular wall thicknesses 
After the mice had been anesthetized and 
taken the blood, their hearts were removed and 
kept individually. In the preparation of histologi-
cal slides, in order to get homogenous parts of ven-
tricular wall myocards, the hearts were cut trans-
versally at the middle level part of cardiac tissues 
were fixed with 4% formaldehyde. Furthermore, 
the heart tissue specimens were dehydrated in 
graded alcohol and embedded in paraffin. Ten se-
rial sections were made transversally (3 µm thick-
ness). These section then were deparaffinized, re-
hydrated, dehydrated, and stained with hematoxy-
lin-eosin (H&E) according to standard method 
[25], and then observed under light microscope. 
Examination of wall thickness on three slides of 
each samples were done under 40× magnifications 
and measured in micrometer (µm). 
 
Statistical analysis 
All of the collected data were tabulated and an-
alyzed statistically using SPSS-21 software (IBM 
SPSS Statistic Processor). The differences of 
means among measured variables were analyzed 
with ANOVA, then continued by Post Hoc and 
Pearson Correlation test. A value of p < 0 05 was  
considered statistically significant.  
 
Results and Discussion 
In order to check the homogeneity of animal 
models, after one-week acclimatization and ran-
domly divided into four groups, all of the 24 mice 
were weighted individually. The body weights of 
mice (mean ± 1SD) were 30.25 ± 2.22 grams for 
aquadest group, 29.50 ± 0.58 grams for L-NAME 
group, 28.75 ± 0.957 grams for captopril group 
and 28.00 ± 2.16 grams for valsartan group respec-
tively. Statistical analysis showed that the body 
weights of mice among groups were not signifi-
cant different (p = 0.265, ANOVA test).  In this 
study administration of L-NAME extract 1.75 
mg/25g BW/day diluted in drinking water for 14 
days, had significantly increased the mice blood 
pressures and successfully made the mice to be hy-
pertensive. The systolic blood pressure (SBP) of 
L-NAME group (208 ± 8.04 mmHg); Captopril 
group (192.25 ± 13.52 mmHg) and Valsartan 
group (199.75 ± 13.47 mmHg) are significantly 
higher than normal/aquadest group (144.75 ± 4.99 
mmHg). It is also shown by the differences of 
MAP of L-NAME group (122.5 ± 2.5 mmHg), 
Captopril group (116.75 ± 4.88 mmHg) and 
valsartan group (119.58 ± 4.77 mmHg) with nor-
mal/aquadest group (99.41 ± 2.34mmHg) (p < 
0.05, ANOVA test). The differences of SBPs and 
MAPs among groups after 14 days induction of L-
NAME extract (pretreatment) are presented on Ta-
ble 1. 
On day 14th post treatment, the SBP mean of 
L-NAME group is still high (224.75 ± 18.8 
mmHg) and significantly higher than normal 
group (151.25 ± 2.21mmHg); Captopril (156.50 ± 
8.34 mmHg) and valsartan group (167 ± 15.13 
mmHg) (p < 0.05). Indeed, the MAP of L-NAME 
group (128.08 ± 6.33mmHg) is also significantly 
higher than normal group (101.41 ± 2.50mmHg); 
captopril group (105.17 ± 2.99 mmHg) and valsar-
tan group (108.75 ± 4.77 mmHg) (p < 0.05). The 
treatment of captopril and valsartan within 14 days 
are able to significantly decrease blood pressures 
compared with L-NAME group (p < 0.05), to be 
as low as normal (p > 0.05). There was no differ-
ence between effects of captopril and valsartan in 
lowering blood pressure (p > 0.05). The level of 
SBPs and MAPs post 14 days treatment are shown  
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on Table 1. 
Plasma renin and sST2 levels were examined  
post treatment only. Plasma renin level of hyper-
tensive mice in L-NAME group (59.44 ± 6.23 
ng/mL) is the highest among others, and signifi-
cantly higher than normal/aquadest group (36.37 
± 1.38 ng/mL) (p < 0.05).  The level of plasma 
renin in captopril (29.54 ± 11.95 ng/mL) and 
valsartan group (23.33 ± 4.94 ng/mL), are signifi-
cantly lower than L-NAME group (p < 0.05) (Ta-
ble 1), but there is no difference between captopril 
and valsartan group them self. In contrast there are 
no differences of plasma level of sST2 among all 
four groups (p > 0.05. ANOVA), as also presented 
on Table 1. .Pearson Correlation Analysis with 2-
tail significance shows that there are significant 
correlations between plasma renin level post treat-
ment with systolic blood pressure (r = 0.700; p = 
0.003) and MAP (r = 0.669; p = 0.005), but not for 
sST2 level, either with SBP (r = -0.067; p = 0.805), 
MAP (r = -0.03; p = 0.91) level of plasma renin (r 
= 0.189; p = 0.48) and regression of LVH (r = 
0.047; p = 0.862). 
There are various types of preclinical models 
of HT, such as surgically induced HT, endocrine 
HT, dietary HT, neurogenic HT, and chemically 
induced HT. The L-NAME induced HT is an ex-
ample of chemically induced HT. In L-NAME hy- 
pertensive animal model, blood pressure values 
are reached between 170 and 190 mmHg after 4 
weeks induction [18]. N-nitro-L-arginine-meth-
ylester (L-NAME) is a nonspecific inhibitor of all 
three NO synthase (NOS) isoforms (neuronal - 
nNOS; inducible - iNOS; endothelial- eNOS) and 
causes an increase of blood pressure in a dose de-
pendent manner when administered orally to the 
experimental animals [19]. In this study we used 
the dose of 1.75 mg/25g BW/day diluted in drink-
ing water, after adjustment of standard dose of 40 
mg/Kg [17,18,19]. The adjusted dose was derived 
from calculating the rat dose by 0.14 as conversion 
factor from rat to mouse [20]. Blood pressures 
rised to increase as confirmed by both the SBPs 
and MAPs after two weeks of L-NAME induction 
(Table 1), and after two weeks of treatment (Table 
1).  This finding coupled with the level of plasma 
renin, since it was still high in L-NAME group, but 
decreases in captopril and valsartan group after the 
next two weeks of treatment (Table 1). This was 
also confirmed by the positive correlations be-
tween plasma renin level with systolic blood  
pressure/SBP (r = 0.700; p = 0.003) and MAP 
(r = 0.669; p = 0.005). Posttest analysis of ACE 
inhibitor (captopril) and angiotensin II type-1 re-
ceptor blocker (valsartan) effect within two weeks 
treatment shows that both were effective in lower- 
Table 1.  Comparisons of blood pressures, level of plasma renin and sST2, and ventricular wall thickness among 
the four groups of study 
 
Variables 
Groups 
Aquadest 
(mean ± 1 SD)  
L-NAME 
(mean ± 1 SD) 
Captopril 
(mean ± 1 SD) 
Valsartan 
(mean ± 1 SD) 
Systolic Blood Pressures 
Pre treatment (mmHg) 
145.60 ± 4.72a 208.00 ± 6.96b 191.00 ± 12.04 b 204.60 ± 15.9 3 b 
Mean Arterial Pressures  
Pre treatment (mmHg) 
98.93 ± 2.30 a 
123.20 ± 2.75 b 116.47 ± 4.28 b 119.40 ± 4.15 b 
Systolic Blood Pressures 
Post treatment (mmHg)  
150.00 ± 3.39 a 
223.40 ± 16.59 b 157.80 ± 7.79 a 168.00 ± 13.11 a 
Mean Arterial Pressures  
Post treatment (mmHg) 
99.73 ± 4.34 a 128.33 ± 5.51 b 105.40 ± 2.64 a 108.9 ± 4.15 a 
  Level of  Plasma Renin 
(ng/mL) 
36.16 ± 10.7 a 
59.06 ± 5.46 b 29.01 ± 10.42 a 24.66 ± 5.21 a 
Level of Plasma sST-2 
(pg/mL)  
1.40 ± 0.60 a 
3.04 ± 0.30 a 2.26 ± 0.52 a 1.90 ± 0.43 a 
Ventricular wall 
thickness (µm) 
853.1 ± 232.74 a 1480.1 ± 281.6 b 1169.7 ± 273.2 a, b 1033.2 ± 217.9 a 
Note: different notation means there is significant different (p < 0.05 ANOVA) 
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ing blood pressure (p>0.05), confirming previous 
studies. [9, 10, 11]. Our results in this study proof  
that oral route of L-NAME in adjusted dose within 
two weeks has successfully inhibited NOS, in-
creased plasma renin level and made the mice 
model to be hypertensive. Renin, the well-known 
enzyme that activates angiotensinogen to angio-
tensin 1, firstly initiates cascade in the RAAS, re-
sulting the increase of blood pressure [26]. Capto-
pril and valsartan have similar effects in enhancing 
nitric oxide production, reducing plasma renin 
level and lowering blood pressure, either through 
bradykinin or AT2 receptor pathway. 
In H&E histological slides examinations we 
found that ventricular wall thickness of –L-NAME 
group (1601.2 ± 88.7µm) is significantly highest 
compared to aquadest (891.4 ± 249.9µm) and 
valsartan group (918.4 ± 99.7 µm) (p < 0.05). The 
ventricular wall thickness of captopril group 
(1169.8 ± 315.5 µm) is seemed to be lower than L-
NAME group, but the difference is not significant 
(p > 0.05). Microscopic sample slides representing 
one group each, are presented on Figure 1. In this 
study we examined the histological specimens of 
hearts using hematoxylin and eosin (H&E) stain- 
ing and measured the left ventricular wall thick-
ness in order to reflect the LVH. The result 
showed that induction of L-NAME within 14 
days, then continued with the next 14 days without 
antihypertensive treatment (totally four weeks in-
duction with L-NAME), resulted in a significant 
thickening of ventricular wall compared with nor-
mal (p < 0.05). Furthermore, both of captopril and 
valsartan were significantly able to reduce the wall 
thickness until nearly normal (Table 1).  
Our results showed that there were also signif-
icant correlation between wall thickness with SBP 
and MAP but not with the level of plasma renin 
and plasma sST2. Although Captopril and valsar-
tan showed similar efficacy in lowering blood 
pressure, valsartan seemed to be more effective in 
reducing ventricular wall thickness (Table 1). The 
low significance may due to the small number of 
samples or measurements of wall thickness of HE 
staining slides. At haematoxylin and eosin (H&E) 
staining for any histopathological examination, 
ideally dystrophic striated muscle pathology can 
be easily assessed on sections stained with H&E. 
In proper staining, haematoxylin will stain eosin-
ophilic structures (e.g. muscle sarcoplasm) pink 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Samples of individual  thickness of ventricular wall representing group. Were measured under light 
microscope in 40x magnification (H&E staining).A=Aquadest, B= L-NAME; C= captopril; D = 
valsartan. Valsartan could significantly reduce the ventricular wall thickness to normal level (D vs A) 
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and eosin will stain basophilic structures (e.g. nu-
clei) dark purple, but it is time-consuming and 
need expertise [29]. Since the LVH is initiated by 
fibrosis process, so that in order to detect early 
process of LVH and to measure the degree of fi-
brosis we suggest to use a specific staining such as 
Masson’s trichrome staining [30], Picrosinus red 
staining which is automatically scanned or im-
munohistochemistry staining, as what Hadi et al. 
had done [30].   
Interestingly, in this study the levels of plasma 
sST2 post treatment did not correlate, either with 
systolic blood pressure, MAP, plasma renin level 
or ventricular wall thickness. In contrast, many 
studies and literatures mentioned that plasma sST2 
is a specific cardiac biomarker which has high 
prognostic value with respect to almost all-cause 
and cardiovascular death including patients with 
myocardial infarction (MI), acute heart failure 
(AHF) and chronic heart failure [15, 27, 28]. Sol-
uble ST2 is also markedly induced in mechani-
cally overloaded cardiac myocytes and serves as 
cardiac stress biomarker which associated with 
LVH [14, 15, 16]. Meta-analysis study performed 
by Aimo et al. (2017) mentioned that plasma sST2 
has prognostic value with respect to all-cause and 
cardiovascular death [31], and associated with car-
diac concentric hypertrophy in patients with met-
abolic syndrome [32]. Circulating sST2 levels also 
correlate with a worse phenotype of disease in-
cluding adverse remodeling and fibrosis, cardiac 
dysfunction, impaired hemodynamics and higher 
risk of progression [33, 34]. Therefore, it was sup-
posed that plasma level of sST2 would increase in 
the early stage of LHV. In this study, induction of 
with L-NAME within two weeks, did not induce 
significant increase of plasma sST2 of mice mod-
els. There was no difference of plasma level of 
sST2s among the four study groups. This finding 
suggests that the level of plasma sST2 is not al-
ways mirroring or correlating with improving or 
worsening of clinical condition, including the ven-
tricular wall fibrosis and thickness. It is relevant 
with the study reported by Yang et al., that in sep-
sis patients sST2 showed moderate correlation 
with MAP but no correlation with LV ejection 
fraction [35]. The serum concentration of sST2 in 
metabolic syndrome patients was not linked to 
age, gender, or history of hypertension or diabetes 
[33]. In the Dallas Heart Study (DHS) sST2 con-
centration were not significantly associated with 
most traditional cardiovascular risk factors or sub-
clinical cardiovascular disease [36]. Ojji et al. [14] 
mentioned that blood pressure in hypertension pa-
tients did not influence sST2 concentration. Wil-
lems et al. [37] also reported that sST2 levels have 
no predictive value for future cardiovascular 
events patients with significant carotid artery ste-
nosis. Malek et al. [38] also mentioned that con-
centration of cardiac biomarkers including sST2 
did not correlate with echocardiography parame-
ters. Study which was done by Gao et al. [39] 
showed that serum IL-33 and sST2 were overex-
pressed in in acute-on-chronic hepatitis B liver 
failure (ACHBLF) and sST2 might potentially 
serve as a prognostic marker for it. We suggest that 
soluble ST2 may not be specific for cardiac stress 
biomarker which associated with LVH and useful 
as predictive tool of future cardiac events any-
more. 
 
Conclusion 
Captopril and valsartan had similar effect in 
lowering plasma renin level, blood pressure and 
LVH regression in Hypertension mice models, 
while sST2 seems to be not involved in this model 
of LVH regression obtained after blocking renin -
angiotensin system. 
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